Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

SynAct Pharma: Interim report January-March 2021

“The first three months have indeed given a strong and convincing start of the new year to SynAct Pharma, when we continued to make significant progress on our projects and put the company in a unique position to be a leader in resolution therapy, a new method for treating inflammation and autoimmune diseases,” said Jeppe Øvlesen, CEOSummary of interim report 2021-01-01 – 2021-03-31 (first quarter) · Consolidated net sales amounted to 0 (0) TSEK. · The Group's profit before tax amounted to -14,070 ( -3,822) TSEK. · The Group's earnings per share amounted to -0.46 (-0.14). ·

Vestas – Interim Financial Report, First Quarter 2021

Vestas Wind Systems A/S, Aarhus, 5 May 2021Company announcement no. 10/2021   Summary: Revenue and EBIT decreased compared to same quarter 2020. Record high combined order backlog as a consequence of the integration of offshore. Full-year guidance maintained. In the first quarter of 2021, Vestas generated revenue of EUR 1,962m – a decrease of 12 percent compared to the year-earlier period. EBIT before special items decreased by EUR 17m to EUR (71)m. This resulted in an EBIT margin before special items of (3.6) percent, compared to (2.4) percent in the first quarter of 2020. Free

Peikko Group recruits 50 new professionals to Sales and Engineering

Peikko Group will recruit 50 new talents for sales and engineering positions during Q2-Q3 of 2021. The new positions will be located in a total of 23 countries: Australia, Belgium, China, Czech Republic, Denmark, Estonia, Finland, France, Germany, Italy, Korea, Latvia, Malaysia, the Netherlands, Poland, Romania, Russia, Singapore, Slovakia, Spain, Switzerland, Turkey, and the United Kingdom. Peikko is looking for local talents to provide its customers an even better and quicker service. Applicants will need to speak the local language and know the local construction culture.

Ilari Hyyrynen appointed as Managing Director of Sibylla Russia

Company announcement, 5 May 2021, 9 am.Ilari Hyyrynen appointed as Managing Director of Sibylla RussiaFollowing the sale of Atria’s Russian subsidiary Pit Product, Ilari Hyyrynen (MBA) has been appointed Managing Director of Sibylla Russia, a fast food chain operating in Russia, Kazakhstan and Belarus, as of 5 May 2021. Ilari Hyyrynen has previously worked as Executive Vice President of Atria Russia business area.Ilari Hyyrynen is a member of Atria Group's Management Team and reports to CEO Juha Gröhn.For additional information, please contact Mr Juha Gröhn, CEO, tel. +358 400 684

Catena Media explores refinancing of existing bonds

Catena Media plc’s current debt financing consists of a senior secured bond loan, ISIN SE0010832154, with a total outstanding nominal amount of EUR 88.5 million and maturity in March 2022. To maintain a prudent maturity profile, Catena Media will explore different refinancing alternatives to replace the existing bond loan. This includes the procurement of bank loans as well as mandating Carnegie Investment Bank to arrange investor meetings to investigate the possibility of issuing a new bond loan, subject to market conditions.   For further information, please contact:   Michael

Alligator’s mitazalimab shown to enhance cancer vaccine

Lund, Sweden, May 5, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy.The published data show that mitazalimab activates dendritic cells and tumor-reactive T cells resulting in enhanced anti-tumor efficacy in combination with a model cancer vaccine. Title: The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells and enhances

Interim Report First Quarter 2021

Yet Another Quarter with Record High Revenues and EbitdaFIRST QUARTER · Revenues increased 42.6% to €48.1 million (33.7). · EBITDA increased 64.2% to €8.6 million (5.2). · The EBITDA margin increased to 17.8% (15.5%). · EBIT increased 66.3% to €6.5 million (3.9). · Earnings after tax increased 140% to €6.1 million (2.5). · Earnings per share, basic and diluted, increased 160% to €0.13 (0.05). SIGNIFICANT EVENTS IN THE QUARTER AND AFTER THE END OF THE QUARTER · Revenues increased 42.6% from Q1 2020 driven by strong development in all segments and the acquisition

Interim report 1 January – 31 March 2021

First QUARTER (1 January – 31 March 2021) · Net sales for the quarter amounted to MSEK 47 (50). · Operating profit/loss before depreciation and amortisation (EBITDA) totalled MSEK 23 (26). · Operating profit/loss (EBIT) was MSEK 7 (7). · Comparable profit/loss before tax amounted to MSEK 4 (-7) and recognised profit/loss before tax was MSEK -4 (-7). · Profit/loss after tax totalled MSEK -4 (-7), corresponding to SEK -0.12 (-0.21) per share. · Operating cash flow was MSEK 15 (10). · Production (formerly Own wind power operations) generated 82 GWh (124) of green

Finnair Traffic Performance in April 2021

Finnair Plc                       Investor News                    5 May 2021 at 9:00 a.m. EEST  The COVID-19 pandemic impact was still visible in the April passenger traffic figures, again very strong month for cargo In April, Finnair carried 80,900 passengers, which was 403.6% more than in April 2020. The COVID-19 impact was clearly visible already then as Finnair operated only a minimum network due to strict and extensive travel restrictions. The number of passengers in April 2021 was 6.3% less than in March 2021 (month-on-month figures are not fully comparable as there is one day

YIT to build a digital supply chain in cooperation with Carinafour

YIT CORPORATION Press Release May 5, 2021 at 09:00 a.m.This union of large and small aims for productivity improvements in the construction industry.In its efforts to develop the productivity of the construction industry, YIT is boldly challenging the familiar models and habits of the industry and partnering up with the Turku-based Carinafour, specialising in productivity improvements in the project industry. The joint goal is to develop the industrial production system of construction and the related supply chain. “Productivity improvements don’t happen spontaneously; they require

QLIFE HOLDING AB INTERIM REPORT 2021, Q1

First sales of CE marked Egoo.Health systemFINANCIAL SUMMARY - FIRST QUARTER 2021 · Revenue in the period amounted to kSEK 11,176 (385). Revenue regards sales of COVID-19 tests from the test service center as well as Egoo.Health devices and capsules for decentralized testing. · EBITDA for the period amounted to kSEK -3,197 (-5,732), and net loss kSEK -6,707 (-8,704). · The total cash flow in the first quarter amounted to kSEK -11,284 (-33,754). · Shareholders equity as of 31 March amounted to kSEK 83,962 (104 063). · Earnings per share before/after dilution for the first

Interim report January - March 2021

Gothenburg, May 5, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2021.Important events during the first quarter · In February, Vicore completed a directed share issue raising 336 MSEK. The share issue was approved at an Extraordinary General Meeting in March. · In March, Vicore reported top-line data  from the mechanistic phase II study in systemic sclerosis and Raynaud's phenomenon (SSc) showing that C21 increased bloodflow in fibrotic tissue. Important events after the period · In May, Vicore announced that it has entered into a

Zengun Group AB (publ) Annual General Meeting 2021

At the Zengun Group AB (publ) Annual General Meeting, held on 22 April 2021, it was resolved to adopt the parent company’s ant the Group’s income statements and balance sheets for the financial year 2020. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2020. The meeting resolved to allocate the profit in accordance with the board of directors’ proposal and supported by the auditor, entailing the profit to be carried forward. The current board of directors, Ulf Jonsson, Henrik Lif, Cecilia Safaee, Jan Örnevik and Tobias Örnevik

Peab builds new swimming pool facility in Uddevalla

Peab has been commissioned to build a new swimming pool facility in the Rimner area in Uddevalla. The customer is Uddevalla Municipality and the contract is worth SEK 350 million.The new swimming pool facility will include a 50 meter pool with ten swimming lanes, a pool for swimming lessons, a Swedish Championship standard pool for 25 meter competitions, a children’s pool and a diving pool integrated into the 50 meter pool.  “We have worked together with Uddevalla Municipality for about a year to produce the documents and plans for the new swimming pool facility. Now we look forward to

CONCENTRIC INTERIM REPORT JANUARY –MARCH 2021

FIRST QUARTER · Net sales: MSEK 432 (456) – sales were down –5% year-on-year. After adjusting for impact of currency (–10%) and Allied Enterprises (+5%) sales year-on-year remained flat. · Operating income: MSEK 95 (87), generating an operating margin of 21.9% (19.1). · Net income for the period: MSEK 72 (60); basic EPS of SEK 1.90 (1.60). · Cash flow from operating activities: MSEK 73 (81); continuing strong cash generation. · Group’s net debt: MSEK –90 (27); gearing ratio of –7% (2). Net remeasurement gain on pension liabilities of MSEK 115 drove the reduction in net debt.

SBB, Interim Report January – March 2021: Profit after tax per ordinary share of class A and B increased to SEK 1.75 (0.94)

SAMHÄLLSBYGGNADSBOLAGET I NORDEN AB (PUBL): Interim Report January – March 2021 in brief: · Rental income was SEK 1,325m (1,341). · Operating surplus was SEK 858m (895). · Cash flow from operating activities before changes in working capital was SEK 389m (421). · Profit before tax increased to SEK 3,117m (1,695), of which: · Profit from property management is included in the amount of SEK 615m (319). The profit from property management includes costs for early repayment of loans and other non-recurring costs of SEK -43m (-147). · Changes in the values of properties

Interim Report January – March 2021

Strong growth in financial and customer key metricsFirst quarter 2021  · Net sales increased 125.4% to SEK 402.1 (178.4) million. Organic sales growth excluding Poster Store amounted to 60.5% as a result of strong market demand. · Gross margin in the period increased to 82.3% (82.2%). The gross margin excluding Poster Store increased to 83.4% (82.2%) with the synergies from the acquisition starting to have a more meaningful impact from Q2 2021. · Operating profit amounted to SEK 67.4 (28.7) million, corresponding to an operating margin of 16.8% (16.1%). · Adjusted EBITA

InDex Pharmaceuticals Holding AB (publ) interim report January – March 2021

The crucial pieces of the puzzle in place for the start of phase III“It has been an intensive beginning of 2021 for InDex, where the crucial pieces of the puzzle for the start of phase III now have fallen into place,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period January – March 2021 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –9.3 (–24.0) million · Result after tax amounted to SEK –9.3 (–24.0) million, corresponding to SEK –0.02 per share (–0.10) before and after dilution · Cash flow from operating activities amounted to SEK –

Saga Pure ASA: Notice to the Ordinary General Meeting in Saga Pure ASA

The Ordinary General Meeting in Saga Pure ASA will take place on 26 May 2021 at 10.00hrs (CET) at the premises of the Company at Sjolyst Plass 2, 7th floor in Oslo, Norway. Shareholders are requested to avail themselves of the possibilities of voting by proxy, as described in the notice of the meeting, and as far as possible to refrain from attending in person. Shareholders may submit their votes electronically in advance. Please see the instructions in the enclosed Notice. The Notice and the corresponding attachments will be available on the company's webpage www.saga-pure.com

Karnov Group reports first quarter results 2021

Good start to the yearFINANCIAL HIGHLIGHTS FIRST QUARTER · Net sales increased to SEK 234 m (212), organic growth was 5%. · EBITA amounted to SEK 95 m (88) with EBITA margin of 40.7% (41.6%). · Adjusted EBITA amounted to SEK 95 m (88) with adjusted EBITA margin of 40.7% (41.6%). · Net result amounted to SEK 40 m (29). · Earnings per share after dilution amounted to SEK 0.40 (0.30). · Adjusted operating cash flow amounted to SEK 104 m (170). CEO flemming breinholt comments on the quarter: We have had a positive start to 2021, with continued growth and solid margins.

Implantica presents the first quarter 2021 on May 12 at 15:00 CEST

Implantica AG (publ) invites investors to a presentation of the first quarter 2021 at 15:00 CEST on May 12. The interim report for the first quarter will be published at 8:00 a.m. CEST on the same day.The presentation will be in English via an audiocast with teleconference: Conference call dial-in: · Sweden: +46 85-055 83 57 · United Kingdom: +44 3333 009269 · United States: +1-833-526-8382 Webcast: · https://tv.streamfabriken.com/implantica-q1-2021 Speakers: · CEO Peter Forsell · CFO Andreas Öhrnberg · VP Operations & IR Nicole Pehrsson  For further

New scientific paper further confirms osteointegration of OssDsign Cranial PSI implants

OssDsign AB (publ) (“OssDsign” or the “Company”) today announced that independent researchers from Uppsala University Hospital, Sweden, have published a scientific paper in Journal of Neurosurgery describing bone integration in patients implanted with OssDsign Cranial PSI. Samples from four studied patients consistently show vascularized bone, integrating the OssDsign implant with surrounding native bone. This reaffirms the positive findings presented in previously published papers and further strengthens the benefits of OssDsign’s custom-made calcium phosphate implants.Patients undergoing

IRLAB publishes recorded speech and company presentation prior to digital AGM

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a video recording for the digital annual general meeting (AGM) 2021 is available on the company's website, www.irlab.se. The video recording includes a speech from the Chair of the board, presentation of the newly proposed board member and company presentation. The video is intended to provide information to shareholders as a basis for the digital postal voting, which is ongoing until 5 May 2021.Due to the continued spread of Covid-19 and to ensure the safety of our shareholders, the annual general meeting will this year be held without

Gaming Innovation Group reports Q1 2021

Gaming Innovation Group Inc. (GiG) reports Q1 2021 revenues of €18.3 million and an EBITDA of €4.6 million.  “The first quarter of 2021 is a strong start to the year and another positive step forward for Gaming Innovation Group, with strong results driven from the work and strategic initiatives pushed through in the last 12 months. We are happy with the overall progress, and look forward to continuing to grow towards our long term objectives”, says Richard Brown, CEO of GiG.  Financial Highlights · Revenues in Q1 2021 were €18.3m (11.2), up 64%, all organic growth · Normalised

There are no items matching the current filter
There are no more items matching the current filter
Back to top